Compare BioNTech SE - ADR (BNTX) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Materials Select Sector SPDR Fund — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Materials Select Sector SPDR Fund trades at $50.63. The key difference: Materials Select Sector SPDR Fund is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | XLB | |
|---|---|---|
Market Cap | $22.86B | — |
Sector | Health | — |
52-Week High | $119.34 | $53.62 |
52-Week Low | $83.89 | $42.23 |
Enterprise Value | $6.53B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
XLB trades at $50.58, down 0.61% with bearish technical signals from moving averages. The materials ETF faces mixed sentiment as recent sector gains appear priced in, though infrastructure trends provide underlying support. Key support sits at $50 with resistance at $51. Recent analysis suggests limited near-term upside despite sector tailwinds from manufacturing and energy security themes.
Outlook remains cautious with technical indicators favoring bearish momentum. The materials sector benefits from infrastructure spending but faces geopolitical sensitivity and valuation concerns after recent gains. Investment opportunity exists for long-term exposure to industrial materials, though current entry timing appears suboptimal given technical weakness and priced-in cyclical recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
